- 中
- 繁
- EN
Beijing, Shanghai & Boston, Jul 26, 2024 — Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today announced that the first patient has been dosed in its Phase I/IIa clinical trial of JAB-30355, a p53 Y220C reactivator, in patients with solid tumors.
P53 is the most frequently altered gene in human cancers, with mutations presented in approximately 50% of all invasive tumors. JAB-30355 is an orally bioavailable small molecule designed to treat patients with solid tumors harboring p53 Y220C mutation.
According to the preclinical results presented by Jacobio at AACR 2024, JAB-30355 is a potent and selective p53 Y220C reactivator. JAB-30355 exhibited dose-dependent anti-tumor activity in multiple CDX and PDX models, with overall good tolerability. The synergistic effect was observed when combined with other anti-cancer agents, indicating a broad potential for combinational therapy with JAB-30355.
Currently, there is only one p53 Y220C activator in phase II stage worldwide. The clinical study of JAB-30335 is being conducted in China and U.S.
Jacobio Pharma (1167.HK) is committed to developing and providing new and innovative products and solutions to improve people's health. Our pipeline revolves around novel molecular targets on six major signalling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB and MYC. We aim for our key projects to be among the top three in the world. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our iADC Platform.
Copyright: JACOBIO PHARMACEUTICALS GROUP CO., LTD. Beijing ICP B 17065868-1 
京公网安备 11030102011242号